Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985823%3A_____%2F16%3A00462469" target="_blank" >RIV/67985823:_____/16:00462469 - isvavai.cz</a>

Alternative codes found

RIV/00023001:_____/16:00060083 RIV/00216208:11130/16:10327758 RIV/00216208:11120/16:43911993 RIV/00064173:_____/16:N0000136

Result on the web

<a href="http://dx.doi.org/10.1097/HJH.0000000000001029" target="_blank" >http://dx.doi.org/10.1097/HJH.0000000000001029</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1097/HJH.0000000000001029" target="_blank" >10.1097/HJH.0000000000001029</a>

Result language

angličtina

Original language name

Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats

Original language description

We evaluated the therapeutic effectiveness of a new, orally active epoxyeicosatrienoic acid analog (EET-A) in rats with angiotensin II (ANG II)-dependent malignant hypertension. Malignant hypertension was induced in Cyp1a1-Ren-2 transgenic rats by activation of the renin gene using indole-3-carbinol (I3C). EET-A treatment was started either simultaneously with I3C induction process or 10 days later during established hypertension. Blood pressure (BP), indices of renal and cardiac injury, and plasma and kidney levels of the components of the renin-angiotensin system (RAS) were determined. In I3C-induced hypertensive rats, early EET-A treatment attenuated BP increase (to 175  3 vs. 193  4 mmHg, on day 13), reduced albuminuria (15  1 vs. 28  2 mg/24 h), and cardiac hypertrophy as compared with untreated I3C-induced rats. This was associated with suppression of plasma and kidney ANG II levels and increases in plasma and kidney angiotensin (1-7) concentrations Remarkably, late EET-A treatment did not lower BP or improve renal and cardiac injury; indices of RAS activity were not affected. The new, orally active EET-A attenuated the development of experimental ANG II-dependent malignant hypertension, likely via suppression of the hypertensiogenic axis and augmentation of the vasodilatory/natriuretic axis of RAS.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FA - Cardiovascular diseases including cardio-surgery

OECD FORD branch

—

Project

<a href="/en/project/GA15-07544S" target="_blank" >GA15-07544S: Cardioprotective and antihypertensive effects of agonistic epoxyeicosatrienoic acids analogs.</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Journal of Hypertension

ISSN

0263-6352

e-ISSN

—

Volume of the periodical

34

Issue of the periodical within the volume

10

Country of publishing house

GB - UNITED KINGDOM

Number of pages

18

Pages from-to

2008-2025

UT code for WoS article

000384032800012

EID of the result in the Scopus database

2-s2.0-84978658313